| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/28/2008 | US20080207565 Use of bisphosphonates for pain treatment |
| 08/28/2008 | US20080207564 Derivaitves of 4-Or 5-Aminosalicylic Acid |
| 08/28/2008 | US20080207563 Synergistic sequential or simultaneous administration of erlotinib and a MEK inhibiting N-substituted-{2,5-dioxo-imidazolidin-1-yl}-3-phenyl-butyramide |
| 08/28/2008 | US20080207562 Conjugates of Hydroxyalkyl Starch and Active Substance, Prepared by Chemical Ligation Via Thiazolidine |
| 08/28/2008 | US20080207560 Blending a phospholipid and a mono- or oligo-glycol ether, together with at least one bioactive component selected from the group consisting of hyaluronic acid and derivatives, vitamin A and derivatives, vitamin C and derivatives, xanthine derivatives, and ubiquinones; improved bioavailability |
| 08/28/2008 | US20080207559 Carbohydrates mixture |
| 08/28/2008 | US20080207558 Activating the sugar by oxidation with nascent bromine generated in situ by reaction between sodium bromide and sodium hypochlorite; complexing with iron (III) chloride hexahydrate; purification, ultrafiltration and heat stabilization; iron deficiency |
| 08/28/2008 | US20080207557 A time-release formulation of a water-soluble derivative having the fatty acid moiety removed and an antiinflammatory agent; opoid resistant neuropathic pain, amputation pain or neuralgia; |
| 08/28/2008 | US20080207556 Product and Process for Inhibition of Biofilm Development |
| 08/28/2008 | US20080207555 Catalyzing the release of ADP-ribose from poly(ADP-ribose) or O-acetyl-ADP-ribose by contacting with an isolated ARH3 polypeptide; modifying DNA repair or chromatin structure by modifying ARH3 polypeptide activity; drug screening; antiinflammatory, antiischemic agents; aging resistance |
| 08/28/2008 | US20080207554 Oligonucleotides with phosphotriester linkages; ribonuclease L activators; antineoplastic agents, namely against leukemias, viricides, parasiticides for Chagas' Disease; nucleotide chemical synthesis |
| 08/28/2008 | US20080207553 Biodegradable Cationic Polymers |
| 08/28/2008 | US20080207552 Decoy compositions for treating and preventing brain diseases and disorders |
| 08/28/2008 | US20080207551 Synthesized using diphosphitylating reagents via solid-phase synthesis; antisense therapy; genetic disorders; anticarcinogenic agents, viricides |
| 08/28/2008 | US20080207550 Immunomodulatory polynucleotides and methods of using the same |
| 08/28/2008 | US20080207549 An antisense polynucleotide or short interfering RNA; diagnosis of proliferative diseases; targets for drug design; antiproliferative agents |
| 08/28/2008 | US20080207548 Immunogenic polynucleotides, expression vectors, antigen presenting host cells, diagnostic kits; cancer vaccines |
| 08/28/2008 | US20080207547 Compositions and methods for the therapy and diagnosis of breast cancer |
| 08/28/2008 | US20080207546 Rna aptamers and methods for identifying the same |
| 08/28/2008 | US20080207545 Using antisense oligonucleotides, small interfering RNA, and ribozymes to inhibit expression of the human steroid 5 alpha-reductase gene and thereby inhibit formation of dihydrotestosterone: skin diseases, hair loss, hirsuitism, and benign prostatic hyperplasia |
| 08/28/2008 | US20080207544 Transfection of retinal cells with a recombinant DNA or ribozyme using a complex of a non-esterified fatty acid, a monoglyceride, a lysophosphatidyl choline, spermine or sperimidine; gene therapy |
| 08/28/2008 | US20080207543 Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy |
| 08/28/2008 | US20080207542 Two double stranded nucleic acids, both with complimentary strands, a cationic lipid, a neutral lipid, and a polyethylene glycol-conjugate; for diagnosis, prevention and prophylaxis of HCV infection, liver failure, hepatocellular carcinoma, and cirrhosis |
| 08/28/2008 | US20080207541 Compositions and Methods For Optimizing Cleavage of Rna By Rnase H |
| 08/28/2008 | US20080207540 Use of LRH-1 response elements derived from the apolipoprotein A1 gene promoter, cells, vectors and genetic constructs to increase HDL levels; atherosclerosis |
| 08/28/2008 | US20080207539 Self-Processing Rna Expression Cassette |
| 08/28/2008 | US20080207538 Enhanced Production of Functional Proteins From Defective Genes |
| 08/28/2008 | US20080207537 Reducing agent and oxidizing agent are separately disposed and sequentially administered to a nail; oxidizer increases permeability; thioglycolic acid derivative and hydrogen peroxide; psoriasis; fungicides |
| 08/28/2008 | US20080207536 Erythromycin-11,12-carbamate derivatives; Grampositive, Gramnegative or anaerobic bacteria; Staphylococcus, Streptococcus, Enterococcus, Hemophilus, Moraxella, Chlamydia, Mycoplasma, Legionella, Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Baccillus or Enterobactericeae |
| 08/28/2008 | US20080207535 Polytetrafluoroethylene (PTFE), polyoxyethylene glycol (PEG), maleic anhydride (MA), and penicillin (ampicillin or gentamicin) are reacted to yield penicillin-PEG-MA-PTFE, which inhibits Grampositive bacteria |
| 08/28/2008 | US20080207534 1,4-benzothiazepine 1,1-dioxide derivative, process for its preparation, medicaments comprising this compound, and use thereof as a hypolipidaemic |
| 08/28/2008 | US20080207533 Pharmaceutical Compositions |
| 08/28/2008 | US20080207532 Use of Nordihydroguaiaretic Acid Derivatives in the Treatment of Drug Resistant Cancer, Viral and Microbial Infection |
| 08/28/2008 | US20080207530 Tritoqualine or isomer, alpha-fluoromethylhistidine, 3-methoxy-5,7,3',4'-tetrahydroxyflavan, naringenin, cyanidanol-3, His-Phe dipeptide, 4-imidazolyl-3-amino-2-butanone, epigallocatechin gallate and other catechins; |
| 08/28/2008 | US20080207524 Medicinal preparations for treating sex hormone-dependent diseases |
| 08/28/2008 | US20080207519 Administering a p38 MAP kinase phosphorylation inhibitor selected from SB202190, SB203580, RWJ 67657, BIRB796, 681323, SCIO-469, SCIO-323, VX-702, and VX-745; skin and pemphigoid autoimmune blistering disorders; inhibiting heat shock protein pathway; |
| 08/28/2008 | US20080207516 Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| 08/28/2008 | US20080207503 Composition and Treatment Methods for Coronary Artery Disease |
| 08/28/2008 | US20080207496 Mixture of staurosporine and drug for transplant rejection |
| 08/28/2008 | US20080207491 Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections |
| 08/28/2008 | US20080207490 Glucose Uptake Modulator and Method for Treating Diabetes or Diabetic Complications |
| 08/28/2008 | US20080206835 Methods and Compositions Relating to Gene Silencing |
| 08/28/2008 | US20080206805 Compounds and Related Methods for Mutant p53 Reactivation |
| 08/28/2008 | US20080206738 Reduce concentration of nitric oxide ; antiinflamamtory agents, stroke, antiproliferative agents; gastrointestinal disorders; inflammatory bowel disorders; antiarthritic agents; Parkinson's disease; Alzheimer's disease;amyotroic lateral sclerosis; anticancer agents |
| 08/28/2008 | US20080206736 Administering a therapeutically effective amount of a flavin N-oxide; exposing flavin N-oxide to an activator, such that activation of the flavin N- oxide results in damage to the DNA in cancer cells without damage to the DNA in normal cells |
| 08/28/2008 | US20080206378 Anthelmintic Composition |
| 08/28/2008 | US20080206371 Novel burn treatment composition |
| 08/28/2008 | US20080206369 Nutritional supplement preparation with piperine |
| 08/28/2008 | US20080206365 2-hydroxy-2-substituted-3,10a-ethanophenanthrolines; inhibitors or activators for cytokine production; viricide, antiarthritic, anticarcinogenic, anticholesterol agents; myocardial infarction, osteoporosis, diabetes complications, sepsis, myeloma, transplant rejection, cirrhosis, AIDS, multiple sclerosis |
| 08/28/2008 | US20080206359 Alpha-/beta-hydroxy acid, dimethicone, volatile silicone, anti-inflammatories/anti-irritants, and cationic polymers; for treatment of razor bumps |
| 08/28/2008 | US20080206348 Cilostazol-Containing Pharmaceutical Composition Based On Particles Of Less Than 50 Micrometers |
| 08/28/2008 | US20080206347 With fatty acid pre-absorbed on surface; for oral administration without causing side effects to the upper gastrointestinal region |
| 08/28/2008 | US20080206341 Lipid Nanoparticles as Vehicles for Nucleic Acids, Process for Their Preparation and Use |
| 08/28/2008 | US20080206340 Galactomannans and/or Glucomannans For Increasing the Bioavailability of Active Substances |
| 08/28/2008 | US20080206338 Controlled release formulations of an alpha-adrenergic receptor antagonist |
| 08/28/2008 | US20080206336 Once-a-day modified release tablet formulation rosiglitazone and metformin; enteric coating to control the rate of release; erosion of coating under pre-determined pH conditions; diabetes mellitus, metabolic syndrome, impaired glucose tolerance or impaired fasting glucose |
| 08/28/2008 | US20080206335 Inert non-pareil core, fluvoxamine layer over core, rate-controlling membrane coating; fluvoxamine released over a period of 12 hours or more; once-daily oral administration |
| 08/28/2008 | US20080206334 Hydrophilic polysaccharide polymer mixture of chitosan, xanthan gum, sodium bicarbonate buffering agent; active agent is dispersed or embedded within the inactive matrix; tablets generated by direct compaction |
| 08/28/2008 | US20080206333 Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| 08/28/2008 | US20080206332 Tablet of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid or a pharmaceutically acceptable salt; polyvinyl acetate phthalate release rate modifying polymer; hydroxypropylmethyl cellulose polymer; neuropathies |
| 08/28/2008 | US20080206331 Tablet comprising efletirizine and pseudoephedrine |
| 08/28/2008 | US20080206330 Pharmaceutical Composition |
| 08/28/2008 | US20080206329 Tablet; water-insoluble release-retarding ethyl cellulose, ammonioalkyl methacrylate copolymer; simple, conventional pharmaceutical processing; no complex retention mechanisms; stable, bioequivalent to commercially available CIPRO XR; maintains therapeutic blood levels; enables once-a-day administration |
| 08/28/2008 | US20080206328 Hypocholesterolemic Compositions Comprising a Statin and an Antiflatulent Agent |
| 08/28/2008 | US20080206327 Phentermine weight-loss drug; excipients, bulking agents, binders, disintegrating agents, acidifying agents, sweetening agents, lubricants, flavorings; child, adolesent obesity |
| 08/28/2008 | US20080206326 Liquid salt of a non-steroidal anti-inflammatory drug, flurbiprofen; propylene glycol solvent; sucrose, glucose, sorbitol, xylitol, maltitol, a hydrogenated starch hydrosylate, molten lozenge-forming composition; sore throats |
| 08/28/2008 | US20080206323 Soft Gelatin Capsules |
| 08/28/2008 | US20080206322 Advantageous properties when administered orally; consistency of pharmacokinetic behavior achieved; exhibits less fatty food interaction; time release coating reduces variation in mycophenolic acid exposure from one day to the next or from day time to night |
| 08/28/2008 | US20080206321 Sucrose acetate isobutyrate; cellulose acetate butyrate; solvent; rheology modifier; opioid drug; dosage form and formulation; desirable release kinetics; not susceptible to crushing or powdering; not susceptible to extraction using ethanol or water; abuse deterrence and reduced risk of diversion |
| 08/28/2008 | US20080206320 Alopecia therapy using tetrazole compound |
| 08/28/2008 | US20080206319 Mucosal adjuvants elicit strong balanced or adjusted immune response of humoral, cellular components; prophylaxis or treatment of infectious diseases or cancer; non-toxic; employed with a wide variety of active ingredients to be assisted in conventional or novel vaccines |
| 08/28/2008 | US20080206316 Nutraceutical; chromium atoms bonded to fatty acids; linoleic acid, linolenic acid, gamma-linolenic acid, arachidonic acid; and transition metal, an alkaline metal, alkaline earth metal, rare earth metal, or metalloid; nutritional supplements, food stuffs, and pharmaceutical compositions |
| 08/28/2008 | US20080206314 patches has pressure-sensitive adhesive matrix containing a polyisobutylene, free of permeation enhancer, for drug deliverying sufentanil through the skin to provide an analgesic effect, pain management; sustained release, side effect reduction, consistent concentration in blood |
| 08/28/2008 | US20080206313 Nutraceutical; vitamin B, amine oxidase enzyme inhibitor of semicarbazide-sensitive amine oxidases; additive to a foodstuff or as a dietary supplement; atherosclerosis, vascular retinopathies, retinopathy, glomerulosclerosis, nephropathy, nephrotic syndrome, polyneuropathy, mononeuropathies |
| 08/28/2008 | US20080206312 Therapeutic Morpholino-Substituted Compounds |
| 08/28/2008 | US20080206311 Sucrase Activity Inhibitor, Glucoamylase Activity Inhibitor and Food and Feed Containing the Same |
| 08/28/2008 | US20080206310 Regimens for Controlled Drug Delivery Devices for Contraception |
| 08/28/2008 | US20080206309 Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorrhagia |
| 08/28/2008 | US20080206308 comprising a biodegradable unsaturated polymer selecting from polypropylene fumarate and polycaprolactone fumarate and a curing agent to form a porous scaffold in an mold or in a body cavity; for tissue regeneration; drug delivery devices; biodegradable, biocompatible scaffolds for tissue engineering |
| 08/28/2008 | US20080206307 Biologically absorbable coatings for implantable devices and methods for fabricating the same |
| 08/28/2008 | US20080206303 Prolonged Release Formulations Comprising Anastrozole |
| 08/28/2008 | US20080206298 Enhanced biological autologous tissue adhesive composition and methods of preparation and use |
| 08/28/2008 | US20080206293 Absorbent substrate with a non-leaching antimicrobial activity and a controlled-release bioactive agent. |
| 08/28/2008 | US20080206292 Cosmetic Method for Targeting of Wrinkles |
| 08/28/2008 | US20080206290 Cosmetic combination product for improving appearance |
| 08/28/2008 | US20080206267 Inactivation Of Genes Of The Mep Pathway |
| 08/28/2008 | US20080206266 Carbohydrate ligand that specifically binds to a leczyme; nucleic acid sequence encoding a nonclassical MHC class I heavy chain; ability to associate with a beta 2 microglobulin; major histocompatibility complex transplantation molecules |
| 08/28/2008 | US20080206265 Using oligonucleotide immunostimulant mixture with drug; Modification of an immunostimulatory oligonucleotide to optimally present 5' ends dramatically enhances its anti-cancer activity |
| 08/28/2008 | US20080206263 Methods and Compositions for Prognosing, Detecting, and Treating Age-Related Macular Degeneration |
| 08/28/2008 | US20080206258 Novel Tetrahydropyridothiophenes |
| 08/28/2008 | US20080206257 Reducing epithelial toxicity during cancer therapy by administering KGF with e.g. erlotinib, Iressa(TM), canertinib, or a monoclonal antibody against EGFR; side effect reduction of diarrhea, rash |
| 08/28/2008 | US20080206253 inhibitor of p38 beta MAP kinase; interfering RNA, short hairpin RNA, ribozyme, antisense oligonucleotide, or protein inhibitor; monoclonal antibody, a polyclonal antibody, a peptide, or a small molecule |
| 08/28/2008 | US20080206252 Novel Polypeptides, and Nucleic Acids Encoding the Same |
| 08/28/2008 | US20080206250 Compositions and methods for the therapy and diagnosis of breast cancer |
| 08/28/2008 | US20080206247 Glycoprotein VI fusion proteins |
| 08/28/2008 | US20080206241 rheumatoid arthritis; e.g., a GM-CSF antibody, and an anti-folate compounds, e.g., methotrexate; but in an amount that does not induce neutropenia |
| 08/28/2008 | US20080206232 Compositions and Methods For Modulating Pgc-1Beta to Treat Lipid-Related Diseases and Disorders |
| 08/28/2008 | US20080206230 Peptides Derived from Human Bplp Protein, Polynucleotides Coding for Said Peptides and Antibodies Directed Against Said Peptides |
| 08/28/2008 | US20080206227 Factor vii conjugates for selectively treating neovascularization disorders |
| 08/28/2008 | US20080206222 Fullerenes; clathrates; side effect reduction |